Patent · US Active

Inhibition of a lncRNA for treatment of neuroblastoma

US11357853B2 · kind B2 · utility

0Cited by

2References

8Claims

0Family size

Assignee

UNIVERSITEIT GENT · BE

Inventors

Dries Rombaut · Evergem, BE
Pieter Mestdagh · Brugge, BE
Steve Lefever · Dendermonde, BE

Key dates

Filing date	Jan 24, 2019
Grant date	Jun 14, 2022
Priority date	—
Expiry date	Jun 24, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A treatment of cancer, particularly the treatment of neuroblastoma. Indeed, the discloses that a particular long non-coding RNA (lncRNA) is specifically up-regulated in neuroblastoma cells as compared to other cancer cells and that high expression of the lncRNA correlates with a lower survival probability. Inhibition of this lncRNA in neuroblastoma cells leads to a reduction in cell growth and induction of apoptosis and is a novel therapeutic strategy in the treatment of neuroblastoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.